Defunct Company
Total Trials
35
As Lead Sponsor
As Collaborator
0
Total Enrollment
3,076
NCT01035671
Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia
Phase: Phase 2
Role: Lead Sponsor
Start: Dec 31, 2009
Completion: Mar 31, 2011
NCT01074359
Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation
Start: Feb 28, 2010
Completion: Nov 30, 2010
NCT01458769
Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz
Phase: Phase 1
Start: Dec 31, 2010
Completion: Apr 30, 2011
NCT01328821
Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499
Start: Mar 31, 2011
Completion: Jun 30, 2011
NCT01460199
Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease
Start: Aug 31, 2011
Completion: Dec 31, 2011
NCT01487109
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Start: Jan 31, 2012
Completion: Jan 31, 2015
NCT02215499
A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Start: Jul 31, 2014
Completion: Nov 30, 2014
NCT02239081
A Safety and Tolerability Study of CTP-730 in Healthy Volunteers
Start: Sep 30, 2014
Completion: May 31, 2015
NCT02392702
Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects
Start: Mar 31, 2015
Completion: Sep 30, 2015
NCT02404922
Multiple Ascending Dose Study in Healthy Volunteers
Completion: Jun 30, 2015
NCT02599792
Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656
Start: Nov 30, 2015
Completion: Apr 30, 2016
NCT02680249
Food Effect Study of CTP-656 in Healthy Male Volunteers
Start: Feb 29, 2016
NCT02777008
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects
Start: May 31, 2016
Completion: Mar 31, 2017
NCT02960945
Open-Label Crossover Study Comparing CTP-543 to Jakafi®
Start: Nov 30, 2016
NCT03137381
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
Start: Aug 9, 2017
Completion: Jul 8, 2019
NCT03778320
A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers
Start: Dec 14, 2018
Completion: Jan 31, 2019
NCT03830463
Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers
Start: Jan 24, 2019
Completion: Mar 28, 2019
NCT03811912
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
Start: Mar 21, 2019
Completion: Nov 21, 2019
NCT03880136
Food Effect Study of CTP-543 in Healthy Volunteers
Start: Mar 25, 2019
Completion: Apr 5, 2019
NCT03880253
Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers
Start: Apr 10, 2019
Completion: May 16, 2019
NCT03941548
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
Start: May 24, 2019
Completion: Apr 10, 2020
NCT04092712
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
Start: Sep 5, 2019
Completion: Sep 20, 2019
NCT04158687
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
Start: Nov 26, 2019
Completion: Dec 22, 2020
NCT04309643
Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects
Start: Jun 9, 2020
Completion: Jul 8, 2020
NCT04518995
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
Phase: Phase 3
Start: Nov 23, 2020
Completion: Apr 19, 2022
NCT04784533
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Start: Feb 26, 2021
Completion: May 16, 2023
NCT04743414
Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects
Start: Mar 2, 2021
Completion: Apr 5, 2021
NCT04843540
Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects
Start: May 19, 2021
Completion: Jul 2, 2021
NCT04797650
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
Start: Jun 10, 2021
Completion: Jun 29, 2022
NCT05192369
A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers
Start: Jan 4, 2022
Completion: Jan 28, 2022
NCT05467722
Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543
Start: Jun 1, 2022
Completion: Sep 21, 2022
NCT05468749
Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543
Start: Jun 6, 2022
Completion: Oct 27, 2022
NCT05467696
Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers
Start: Jun 14, 2022
Completion: Jul 1, 2022
NCT05467709
Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects
Start: Jun 21, 2022
Completion: Jul 7, 2022
NCT05478772
Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects
Start: Jul 11, 2022
Completion: Aug 12, 2022